Pharmaceutical

BioVersys secures patent claims in China for BV100

BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.

Apr 2, 2025 - 06:00
BioVersys secures patent claims in China for BV100
BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.
Read the original article

Tags:

Previous Article

Platform trials: The challenges, benefits, and best practices to maximize result...

Next Article

FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Six months after launch, Bert Vogelstein’s latest blood testing startup gets acquired for $450 million

STAT+: Six months after launch, Bert Vogelstein’s lates...

Apr 27, 2023

Sellas presses ahead with fast track designation for lymphoma

Sellas presses ahead with fast track designation for ly...

Oct 31, 2023

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions

Psoriasis biosimilars and pricing changes herald treatm...

Nov 1, 2024